Research and analysis

RPC opinion: The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Restrictions on Private Sales and Supplies) Order 2024 impact assessment

The RPC's opinion of the Department of Health and Social Care's impact assessment.

• From: Regulatory Policy Committee
• Published: 10 February 2025

Documents

RPC opinion: The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Restrictions on Private Sales and Supplies) Order 2024 impact assessment

PDF, 124 KB, 7 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email enquiries@rpc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Restrictions on Private Sales and Supplies) Order 2024 implements an indefinite ban on the sale and supply of puberty blockers to under 18s by private UK providers and prescribers in the European Economic Area and Switzerland.

The Regulatory Policy Committee (RPC) gave a ‘green’ rating to the impact assessment on 10 February 2025. This means that we considered it to be fit for purpose based on our scrutiny of the evidence and analysis supporting the case for why regulation is necessary. 

The RPC’s opinion refers to the evidence and analysis presented in the impact assessment, not the policy itself.

Published 10 February 2025